Dental Implant Treatment in Patients Treated with Systemic Ivdelivery of Zoledronate (Bisphosphonates) for the Treatment of Osteoporosis

Abstract

Introduction: Intravenous (IV) administration of Bisphosphobates has in general been considered an absolute contraindication for elective surgery, including dental implant placement, due to the increased risk for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). Materials and methods: Reporting the case of a patient who received a dental implant while in treatment with iv Zoledronic Acid, this presentation aims to review the current evidence and identify the factors of importance for decision-making in such cases. Discussion: The evidence with regards to IV administration of Bisphosphonates, mainly originates from patients treated for various forms of metastatic cancer, which requires a medication scheme significantly different than in the treatment of osteoporosis. As iv infusion of Bisphosphonates is becoming an increasingly utilised treatment modality for the treatment of Osteoporosis, it is important to identify the factors of importance for clinical decision making in such cases and differentiate from the general risks of procedures related to the treatment of cancer.